Revenue: As of FY2025 Q4, the actual value is USD 434.93 M, beating the estimate of USD 429.62 M.EPS: As of FY2025 Q4, the actual value is USD -0.02, missing the estimate of USD 0.4425.EBIT: As of FY2025 Q4, the actual value is USD 42.35 M.英特格拉生命科学 (Integra LifeSciences Holdings Corporation) reported its financial results for the fourth quarter and full year ended December 31, 2025, and provided 2026 financial guidance . The company prepares reconciliations of GAAP measures to non-GAAP measures, including organic revenues, adjusted net income, adjusted EBITDA, adjusted gross profit and margin, adjusted earnings per diluted share, net debt, free cash flow, and adjusted free cash flow conversion .<h4>Fourth Quarter 2025 Financial Summary</h4><ul><li>Reported Revenues: $434.9 million, a decrease of 1.7% on a reported basis and 2.5% on an organic basis compared to the fourth quarter of 2024 .</li><li>GAAP Net Loss: -$1.7 million, compared to GAAP net income of $19.4 million in the prior year .</li><li>Adjusted Net Income: $63.7 million, compared to $73.3 million in the fourth quarter of 2024 .</li><li>Adjusted EBITDA: $104.2 million, compared to $104.9 million in the fourth quarter of 2024 . As a percentage of revenue, adjusted EBITDA was 24.0%, compared to 23.7% in the prior year .</li><li>Adjusted Gross Profit: $268.400 million .</li><li>Adjusted Gross Margin: 61.7% .</li><li>Operating Income: $23.040 million .</li><li>Cost of Goods Sold: $214.060 million .</li><li>Research and Development: $24.791 million .</li><li>Selling, General and Administrative: $169.267 million .</li><li>Cash Flows from Operations: $11.8 million .</li><li>Capital Expenditures: $17.2 million .</li><li>Adjusted Free Cash Flow: -$5.399 million .</li><li>Adjusted Free Cash Flow Conversion: -8.5% .</li></ul><h4>Fourth Quarter 2025 Segment Performance</h4><ul><li>Codman Specialty Surgical: Total revenues were $323.3 million, representing 75% of total revenues, an increase of 2.7% on a reported basis and 1.6% on an organic basis compared to the fourth quarter of 2024 . Sales in Neurosurgery grew 1.4% organically, Instruments grew 2.3% organically, ENT sales grew 2.2% organically, and International sales grew high-single digits organically .</li><li>Tissue Technologies: Total revenues were $111.6 million, representing 25% of total revenues, a decrease of 12.8% on both a reported and organic basis compared to the fourth quarter of 2024 . Sales in Wound Reconstruction declined 21.4% organically, while Private Label sales grew 20.1% organically .</li></ul><h4>Full-Year 2025 Financial Summary</h4><ul><li>Reported Revenues: $1,635.2 million, an increase of 1.5% from the prior year, with organic sales down 0.7% compared to 2024 .</li><li>GAAP Net Loss: -$516.5 million, primarily driven by a $511 million goodwill impairment charge recorded in the second quarter .</li><li>Adjusted Net Income: $171.4 million, compared to $196.9 million in the prior year .</li><li>Adjusted EBITDA: $317.5 million, a decrease of $4.7 million versus the prior year .</li><li>Adjusted EBITDA Margins: 19.4%, a decrease of 60 basis points from the prior year period .</li><li>Adjusted Gross Profit: $1,011.524 million .</li><li>Adjusted Gross Margin: 61.9% .</li><li>Operating Loss: -$493.370 million .</li><li>Cost of Goods Sold: $803.625 million .</li><li>Research and Development: $98.971 million .</li><li>Selling, General and Administrative: $699.700 million .</li><li>Goodwill Impairment Charge: $511.365 million .</li><li>Cash Flow from Operations: $50.4 million .</li><li>Capital Expenditures: $81.4 million .</li><li>Net Debt: $1,595.622 million .</li><li>Consolidated Total Leverage Ratio: 4.5x .</li><li>Total Liquidity: Approximately $516 million, including $263.7 million in cash plus short-term investments .</li><li>Adjusted Free Cash Flow: -$31.052 million .</li><li>Adjusted Free Cash Flow Conversion: -18.1% .</li></ul><h4>Outlook / Guidance</h4>For the full-year 2026, 英特格拉生命科学 (Integra LifeSciences Holdings Corporation) expects revenues to be in the range of $1,662 million to $1,702 million, representing reported growth of 1.6% to 4.1% and organic growth of 0.8% to 3.3% . Adjusted earnings per diluted share are anticipated to be between $2.30 and $2.40 . For the first quarter of 2026, the company projects reported revenues between $375 million and $390 million, with adjusted earnings per diluted share in the range of $0.37 to $0.45 .

Integra LifeSciences | 8-K: FY2025 Q4 Revenue Beats Estimate at USD 434.93 M